News | December 11, 2013

Federal Court Shuts Down Patent Infringement Claim Against AccessClosure

December 11, 2013 — AccessClosure Inc. announced that the U.S. Court of Appeals for the Federal Circuit denied a request by St. Jude Medical Inc. to rehear an appeal on a double patenting ruling concerning its U.S. Patent No. 7,008,439 (the “Janzen ’439 patent"), covering technologies to close holes in arteries.
 
The U.S. Court of Appeals’ decision, holding the Janzen ’439 patent invalid, supports the original jury verdict on Dec. 21, 2010 in the U.S. District Court for the Western District of Arkansas. The U.S. Court of Appeals will send the case back to the Texarkana District Court Dec. 16, 2013, when it issues its mandate.
 
“This is an outstanding day for our company," said Gregory Casciaro, president and CEO, AccessClosure Inc. “The court’s ruling on Janzen ‘439 is an important vindication that ends years of legal distraction. The timely decision allows the AccessClosure team to finally put this dispute behind us and enter 2014 with a clear focus on developing and delivering innovative, patient-friendly closure solutions and continuing to invest in new technologies that improve both the doctor and patient experience.”
 
This week’s positive final ruling came after the U.S. Court of Appeals upheld a separate ruling, requiring the company to pay $27.1 million in compensatory damages to St. Jude Medical for infringing the Fowler family of patents with products distributed prior to October 2010, when those patents expired. Once the case is returned to the Texarkana District Court, a final accounting and determination of additional damages, if any, will be determined as it relates to the Fowler patents. The significance of this week's ruling on Janzen '439 is that AccessClosure no longer faces any threat of an injunction from St. Jude Medical because the Janzen ’439 patent was held to be invalid.
 
"While we maintain that our products do not utilize St. Jude technology, we are prepared to comply with the award decision related to the Fowler patent family and put all legal proceedings behind us,” said Casciaro.
 
For more information: www.accessclosure.com

Related Content

Feature | Vascular Access | Dave Fornell, Editor

Vascular access site bleeding is associated with higher complications and mortality rates. For decades femoral access ...

Home June 10, 2020
Home
News | Vascular Access

June 8, 2020 – BD (Becton, Dickinson and Company) launched the Halo One Thin-Walled Guiding Sheath, designed to perform ...

Home June 08, 2020
Home
News | Vascular Access

November 6, 2019 — Saranas Inc. announced completion of the first U.S. commercial case using its Early Bird Bleed ...

Home November 07, 2019
Home
Technology | Vascular Access

September 3, 2019 — New Zealand-based Adept Medical announced the launch of the Antegrade IR Platform. Clinically driven ...

Home September 03, 2019
Home
News | Vascular Access

May 31, 2019 — Terumo Medical Corp. is recalling the SoloPath Balloon Expandable TransFemoral System and Re-Collapsible ...

Home May 31, 2019
Home
News | Vascular Access

October 4, 2017 — TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European ...

Home October 04, 2017
Home
News | Vascular Access

March 31, 2017 — The U.S. Food and Drug Administration (FDA) announced it has initiated a Class I recall of the Merit ...

Home March 31, 2017
Home
News | Vascular Access

January 31, 2017 — Bard Peripheral Vascular Inc. is recalling the Halo One Thin-Walled Guiding Sheath because the sheath ...

Home January 31, 2017
Home
Technology | Vascular Access

January 10, 2017 — Teleflex Inc. announced that its Arrow VPS Rhythm Device with optional TipTracker technology has been ...

Home January 10, 2017
Home
News | Vascular Access

September 20, 2016 — Teleflex Inc. recently displayed its vascular access technologies and a new educational platform ...

Home September 20, 2016
Home
Subscribe Now